Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model

Yoo, George H.; Subramanian, Geetha; Ezzat, Waleed H.; Tulunay, Ozlem E.; Tran, Vivian; Lonardo, Fulvio; Ensley, John F.; Kim, Harold; Won, Joshua; Stevens, Timothy P.; Zumstein, Louis; Lin, Ho Sheng

doi:10.1016/j.amjoto.2008.10.002

Cited by 4 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of Ad-p53 and docetaxel resulted in enhanced antitumor effects in a murine model of HNSCC 105 . Docetaxel was shown to upregulate CAR in HNSCC cells and cooperate with Ad-p53 to increase the expression of bax and the cleavage of PARP and caspase-3 106 .…”

Section: Adenovirus-p53 In Prostate Cancermentioning

confidence: 96%

Improving adenoviral vectors and strategies for prostate cancer gene therapy

Tamura¹,

Luna²,

Lana³

et al. 2018

Clinics

View full text Add to dashboard Cite

Gene therapy has been evaluated for the treatment of prostate cancer and includes the application of adenoviral vectors encoding a suicide gene or oncolytic adenoviruses that may be armed with a functional transgene. In parallel, versions of adenoviral vector expressing the p53 gene (Ad-p53) have been tested as treatments for head and neck squamous cell carcinoma and non-small cell lung cancer. Although Ad-p53 gene therapy has yielded some interesting results when applied to prostate cancer, it has not been widely explored, perhaps due to current limitations of the approach. To achieve better functionality, improvements in the gene transfer system and the therapeutic regimen may be required. We have developed adenoviral vectors whose transgene expression is controlled by a p53-responsive promoter, which creates a positive feedback mechanism when used to drive the expression of p53. Together with improvements that permit efficient transduction, this new approach was more effective than the use of traditional versions of Ad-p53 in killing prostate cancer cell lines and inhibiting tumor progression. Even so, gene therapy is not expected to replace traditional chemotherapy but should complement the standard of care. In fact, chemotherapy has been shown to assist in viral transduction and transgene expression. The cooperation between gene therapy and chemotherapy is expected to effectively kill tumor cells while permitting the use of reduced chemotherapy drug concentrations and, thus, lowering side effects. Therefore, the combination of gene therapy and chemotherapy may prove essential for the success of both approaches.

show abstract

Section: Adenovirus-p53 In Prostate Cancermentioning

confidence: 96%

Improving adenoviral vectors and strategies for prostate cancer gene therapy

Tamura¹,

Luna²,

Lana³

et al. 2018

Clinics

View full text Add to dashboard Cite

show abstract

“…It is important to note that this altered ECM is a particular issue for nanoparticles due to the sheer size of the systems, particularly in comparison to free drug (Holback & Yeo, 2011). There has been a considerable amount of work done looking at intratumoral delivery of free anticancer drugs such as docetaxel (Yoo et al, 2010), cisplatin (Celikoglu et al, 2006a,b), and paclitaxel (Wang & Chen, 2012). Celikoglu group has produced some comprehensive reviews of the delivery of cytotoxic drugs by intratumoral injection, particularly via bronchoscopy and there appears to be a considerable opportunity to achieve even more in this treatment modality (Celikoglu et al, 2008(Celikoglu et al, , 2010.…”

Section: Intratumoral Injectionmentioning

confidence: 99%

“…As discussed in these reviews, the mainstay of treatment for inoperable tumors in the lung has been external beam radiation; however, it is becoming increasingly obvious that this mode of treatment is insufficient as these patients continue to have and extremely poor prognosis. In a 2010 study (Yoo et al, 2010), p53 viral vectors were co-delivered with docetaxel to tumors in mice and produced an impressive and significant reduction in tumor size in treated animals compared to the control group and almost-complete tumor suppression was even observed. In this study, the animals had to receive biweekly intratumoral injections, as the drug cannot be retained within the tumor, which appears a significant drawback of almost all of the studies looking into intratumoral injection of solutions of free drug.…”

Section: Intratumoral Injectionmentioning

confidence: 99%

Loco-regional administration of nanomedicines for the treatment of lung cancer

et al. 2015

View full text Add to dashboard Cite

Lung cancer poses one of the most significant challenges to modern medicine, killing thousands every year. Current therapy involves surgical resection supplemented with chemotherapy and radiotherapy due to high rates of relapse. Shortcomings of currently available chemotherapy protocols include unacceptably high levels of systemic toxicity and low accumulation of drug at the tumor site. Loco-regional delivery of nanocarriers loaded with anticancer agents has the potential to significantly increase efficacy, while minimizing systemic toxicity to anticancer agents. Local drug administration at the tumor site using nanoparticulate drug delivery systems can reduce systemic toxicities observed with intravenously administered anticancer drugs. In addition, this approach presents an opportunity for sustained delivery of anticancer drug over an extended period of time. Herein, the progress in the development of locally administered nanomedicines for the treatment of lung cancer is reviewed. Administration by inhalation, intratumoral injection and means of direct in situ application are discussed, the benefits and drawbacks of each modality are explored.

show abstract

Current World Literature

2011

Current Opinion in Otolaryngology &Amp; Head &Amp; Neck Surgery

View full text Add to dashboard Cite

Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model

Cited by 4 publications

References 31 publications

Improving adenoviral vectors and strategies for prostate cancer gene therapy

Improving adenoviral vectors and strategies for prostate cancer gene therapy

Loco-regional administration of nanomedicines for the treatment of lung cancer

Current World Literature

Contact Info

Product

Resources

About